🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Abbisko Therapeutics clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China and USA registers with Abbisko Therapeutics as lead sponsor. Synced 26 Sep 2026
21Current trials
13Recruiting now
9Drugs in these trials
2Trial registers
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Abbisko Therapeutics is the lead sponsor of 21 current clinical trials in our China and USA registers. 13 are recruiting patients now. The most common phase is Phase 1. The drugs named most often in its trials are Pimicotinib, ABSK-011 and ABSK043. The most-studied condition is Non-Small Cell Lung Cancer.

ClinicalTrials.gov trials by status

  • Recruiting1362%
  • Not yet open314%
  • Active, closed314%
  • By invitation210%

Trials by phase

  • Phase 1943%
  • Phase 2838%
  • Phase 1/2210%
  • Phase 315%
  • Observational15%
01

Clinical trials sponsored by Abbisko Therapeutics

21 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
A Study to Evaluate the Effects of Low-Fat Meal, High-Fat Meal and Omeprazole Enteric-Coated Tablets on the Pharmacokinetics of ABSK-011 Capsules in Healthy Participants
NCT07700953 · ClinicalTrials.gov ↗ · Healthy Participants
Drug: ABSK-011
Phase 1 Recruiting 2026-07 China
A Phase 2 Clinical Study of ABSK061 and ABSK043
NCT06632262 · ClinicalTrials.gov ↗ · HER2-Gastric/Gastroesophageal Junction Cancer, Urothelial Carcinoma, Non-Small Cell Lung Cancer
Phase 2 Recruiting 2024-11 China
A Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer
NCT06111274 · ClinicalTrials.gov ↗ · Advanced Pancreatic Cancer
Phase 2 Recruiting 2023-10 China
A Phase I/II Study of ABSK141 in Patients With Advanced Solid Tumors ( ABSK141-101 )
NCT07417189 · ClinicalTrials.gov ↗ · Solid Tumors, Adult
Drug: Afatinib
Phase 1/2 Recruiting 2026-03 China
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-011 in Patients With Advanced Solid Tumor
NCT04906434 · ClinicalTrials.gov ↗ · Advanced Liver Cancer
Drug: ABSK-011
Phase 1 Recruiting 2020-02 USA, China
A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib
NCT06668103 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer With EGFR Mutation
Phase 2 Recruiting 2024-11 China
A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK112 in Patients With Non-Small Cell Lung Cancer
NCT06225804 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer
Phase 1 Recruiting 2024-02 USA, China
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor
NCT04192344 · ClinicalTrials.gov ↗ · Neoplasms, Tenosynovial Giant Cell Tumor
Phase 1 Recruiting 2020-01 USA, China
A Early Study of ABSK131 in Patients With Advanced/Metastatic Solid Tumors
NCT07288957 · ClinicalTrials.gov ↗ · Solid Tumors (Phase 1)
Phase 1 Recruiting 2025-07 China
ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
NCT07327034 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma (HCC)
Drug: ABSK-011
Phase 2 Recruiting 2025-06 China
A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Glecirasib
NCT07164170 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer
Phase 2 Recruiting 2025-09 China
A Phase I Study of ABSK211 in Participants With Advanced Solid Tumors With KRAS Alteration
NCT07718165 · ClinicalTrials.gov ↗ · Solid Tumor (Phase I)
Phase 1 Recruiting 2026-08 China
A Study in Children With Achondroplasia
NCT07301463 · ClinicalTrials.gov ↗ · Achondroplasia
Observational Recruiting 2025-06 China
A Mass Balance Study of [14C]ABSK011
NCT06896760 · ClinicalTrials.gov ↗ · Healthy Subjects
Phase 1 Not yet open 2025-04 China
A Study of ABSK061 to Assess Safety, Tolerability, Pharmacokinetics, and Efficacy in Children With Achondroplasia
NCT07297875 · ClinicalTrials.gov ↗ · Achondroplasia
Drug: ABSK061
Phase 1/2 Not yet open 2025-12 China
A Phase 2 Study of ABSK043 Combined With Osimertinib
NCT07710612 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer With EGFR-mutated and PD-L1 Positive
Phase 2 Not yet open 2026-08 China
A Phase II Study Evaluating the Efficacy and Safety of ABSK021 (Pimicotinib)) in the Treatment of cGvHD Chronic Graft Versus Host Disease (cGvHD)
NCT06186804 · ClinicalTrials.gov ↗ · cGvHD
Phase 2 By invitation 2023-05 China
A Phase 2, Open-Label Study of ABSK-011 Combined Atezolizumab or SOC in HCC Patients
NCT05441475 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma
Drug: ABSK-011
Phase 2 By invitation 2021-12 China
A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK121-NX in Patients With Advanced Solid Tumors
NCT05627063 · ClinicalTrials.gov ↗ · Solid Tumor
Phase 1 Active, closed 2023-06 USA, China
Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER)
NCT05804045 · ClinicalTrials.gov ↗ · Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis, Giant Cell Tumor of Tendon Sheath
Phase 3 Active, closed 2023-04 USA, China
A Study to Evaluate the Effect of a High-fat Meal on the Exposure of Pimicotinib Capsule in Healthy Subjects
NCT06884072 · ClinicalTrials.gov ↗ · Healthy Subjects
Phase 1 Active, closed 2025-04 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Abbisko Therapeutics trials

9 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Abbisko Therapeutics trials

22 conditions
Non-Small Cell Lung Cancer3Tenosynovial Giant Cell Tumor2Healthy Subjects2Achondroplasia2Solid Tumor1Advanced Liver Cancer1Neoplasms1Pigmented Villonodular Synovitis1Giant Cell Tumor of Tendon Sheath1Healthy Participants1HER2-Gastric/Gastroesophageal Junction Cancer1Urothelial Carcinoma1Solid Tumors1Advanced Pancreatic Cancer1Solid Tumors, Adult1Non-Small Cell Lung Cancer With EGFR Mutation1cGvHD1Hepatocellular Carcinoma1Solid Tumors (Phase 1)1Non-Small Cell Lung Cancer With EGFR-mutated and PD-L1 Positive1Hepatocellular Carcinoma (HCC)1Solid Tumor (Phase I)1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China2113
Clinical trials in USA53

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Non-Small Cell Lung Cancer

SponsorTrials
Sichuan Baili Pharmaceutical15
AstraZeneca13
Merck Sharp & Dohme9
Hoffmann-La Roche7
Daiichi Sankyo5
Hunan Province Tumor Hospital5
Shanghai Pulmonary Hospital, Shanghai, China4
Shanghai Chest Hospital4
BioNTech3
Dizal Pharmaceuticals3

Sponsors with the most current trials registered for this condition.

06

Questions about Abbisko Therapeutics trials

How many clinical trials does Abbisko Therapeutics sponsor?

Abbisko Therapeutics is the lead sponsor of 21 current trials on ClinicalTrials.gov in our China and USA registers, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Abbisko Therapeutics trials recruiting?

Yes. 13 of its 21 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Abbisko Therapeutics testing?

Its current trials name 9 drugs and biologicals as interventions. The most frequent are Pimicotinib (5), ABSK-011 (4), ABSK043 (4), ABSK061 (2) and Afatinib (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.